Physician profile
John C Lynam
NPI 1265671127
$10,632.89
in general payments reported to CMS, 2019-2025
37 companies · $6,245 in 2025
The $6,245 reported for 2025 was more than what 92% of Urology providers received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $557 · 2020: $414 · 2021: $215 · 2022: $672 · 2023: $1,047 · 2024: $1,482 · 2025: $6,245.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,312 · Consulting Fee: $3,764 · Education: $629 · Travel and Lodging: $68.88.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,312.30 |
| Consulting Fee | $3,764.00 |
| Education | $629.10 |
| Travel and Lodging | $68.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ferring Pharmaceuticals INC. | $4,439.53 | 2024-2025 | Adstiladrin |
| Astellas Pharma US INC | $1,350.78 | 2019-2025 | Xtandi |
| Teleflex LLC | $574.06 | 2023-2025 | Urolift, Solesta, Barrigel |
| Bayer Healthcare Pharmaceuticals INC. | $549.29 | 2019-2025 | |
| Medtronic, INC. | $453.35 | 2025 | Interstim |
| Axonics, INC. | $447.49 | 2023-2024 | Axonics, Bulkamid |
| Telix Pharmaceuticals | $348.13 | 2023-2025 | Illuccix |
| Janssen Biotech, INC. | $318.26 | 2019-2025 | Erleada |
| Endo Pharmaceuticals INC. | $276.40 | 2019-2023 | Xiaflex |
| Pfizer INC. | $206.06 | 2023-2025 | |
| Antares Pharma, INC. | $170.57 | 2019-2022 | |
| Tolmar, INC. | $158.79 | 2023-2025 | Eligard, Jatenzo |
| Olympus America INC. | $145.56 | 2022 | |
| Abbvie INC. | $124.29 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $112.28 | 2023-2025 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $107.13 | 2023-2025 | Gemtesa, Orgovyx |
| Dendreon Pharmaceuticals LLC | $100.31 | 2020-2025 | Provenge |
| Boston Scientific Corporation | $95.86 | 2019-2021 | |
| Tolmar Pharmaceuticals, INC. | $94.25 | 2019-2020 | |
| Seagen INC. | $84.99 | 2025 | |
| Tempus Ai, INC | $54.83 | 2024 | |
| Blue Earth Diagnostics | $50.16 | 2024-2025 | Posluma |
| Amgen INC. | $44.57 | 2020 | |
| Accord Healthcare, INC. | $41.58 | 2023-2024 | |
| Merck Sharp & Dohme LLC | $39.14 | 2024 | Keytruda, Bridion |
| Bioprotect Medical, INC. | $32.06 | 2024-2025 | Bioprotect Balloon Implant System |
| Coloplast Corp | $31.41 | 2019 | |
| Progenics Pharmaceuticals, INC. | $24.92 | 2025 | |
| Urovant Sciences INC | $24.73 | 2021 | |
| Urogen Pharma, INC. | $23.80 | 2024 | |
| Healthtronics Stone Solutions, LLC | $21.80 | 2022 | |
| Cook Medical LLC | $21.38 | 2021 | |
| Procept Biorobotics Corporation | $19.47 | 2022 | |
| Clarus Therapeutics INC. | $17.77 | 2021 | |
| Foundation Medicine, INC. | $15.77 | 2020 | |
| Metuchen Pharmaceuticals | $12.12 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Lynam listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.